Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Debiopharm Group, a global biopharmaceutical company, and Pharmaleads, a drug discovery and early development company, have signed an exclusive license agreement for the development, registration and commercialization of a small molecule called Debio 0827 or PL37, about to enter Phase I clinical trials.
Subscribe to our email newsletter
Under the terms of the agreement, Debiopharm will make an up-front payment to Pharmaleads, as well as further payments as Pharmaleads reaches predefined development milestones.
Following authorization from the French Medicine Agency, Afssaps, Debio 0827 is about to enter a single ascending dose Phase I, randomised, double-blind, placebo controlled single oral dose escalation study in France, to investigate its safety, tolerability and pharmacokinetics in healthy volunteers.
Rolland-Yves Mauvernay, president and founder of Debiopharm Group, said: “With this agreement we add the new therapeutic area of chronic pain management to the Debiopharm product portfolio. There is currently an unmet medical need for the treatment of chronic pain, which can often not be treated successfully and can seriously affect patients’ quality of life. For this reason, we have decided to develop this new therapeutic approach.”